Table 2.
sActRIIB administration attenuates progeroid phenotypes of Ercc1 Δ/− mice
| Symptoms | Age at onset (weeks) | Change of onset (weeks) | # of Ercc1Δ/− mice (Mock, sActRIIB) | |
|---|---|---|---|---|
| Mock | sActRIIB | |||
| Clasping | 5.00 | 4.80 | −0.20 | (10, 10) |
| Tremors | 11.40 | 12.10 | 0.70 | (10, 10) |
| Severe tremors | 11.60 | 16.11 | 4.51 | (10, 9) |
| Body weight decline | 11.80 | 13.60 | 1.80 | (10, 10) |
| Kyphosis | 17.75 | 18.15 | 0.40 | (10, 10) |
| Imbalance | 18.95 | 18.33 | −0.62 | (10, 3) |
| Paresis | 20.50 | 18.80 | −1.67 | (6, 3) |
The average age at onset of characteristic progeroid phenotypes in treated Ercc1 Δ/− mice and the difference between the group averages is shown. The last column indicates the total number of mice out of 10 per group that displays the phenotype before end of life. Phenotypes delayed more than 0.5 weeks on average or absent in mice treated with sActRIIB compared with mock treated Ercc1 Δ/− mice are indicated in bold. sActRIIB, soluble activin receptor type IIB.